白蛋白结合型紫杉醇治疗复发性卵巢癌及输卵管癌和原发腹膜腺癌的近期疗效和安全性观察  

The Efficacy and Safety of Album in-bound Paclitaxel Based Chem otherapy in Recurrent Epithelial Ovarian Cancer,Fallopian Tube Carcinoma and Primary Peritoneal Cancer

作　　者：张楠[1,2] 郑虹[1,2] 

机构地区：[1]北京大学肿瘤医院 [2]北京市肿瘤防治研究所 恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《实用妇产科杂志》2015年第9期665-668,共4页Journal of Practical Obstetrics and Gynecology

摘　　要：目的：对白蛋白结合型紫杉醇（NAB-P）治疗复发性卵巢癌、输卵管癌及原发腹膜腺癌的近期疗效及安全性进行分析。方法：收集复发性卵巢癌、输卵管癌及原发腹膜腺癌患者共21例,分析NABP为基础的化疗方案、治疗过程中血清CA125检测值、相关临床及药物不良反应资料。采用实体瘤疗效评价标准（RECIST）以及国际妇癌协会（GCIG）的CA125反应评价标准评估疗效。通过治疗方案的中断情况及患者发生的不良反应评估以NAB-P为基础方案的耐受性。结果：21例患者中,无铂间期〉6个月者占33.3%（7/21）,无铂间期〈6个月者占66.7%（14/21）。6例患者在NAB-P基础方案治疗后出现缓解,有效率为28.6%（6/21）。CA125升高患者的有效率为33.3%（6/18）,均为完全缓解。无铂间期〉6个月者的有效率为42.9%（3/7）,无铂间期〈6个月者的有效率为21.4%（3/14）,两者比较差异无统计学意义（P〉0.05）。仅4例患者因血小板减少Ⅲ度、白细胞减少Ⅲ-Ⅳ度或中性粒细胞减少Ⅲ-Ⅳ度停止化疗。结论：NAB-P为基础的化疗方案在接受过多线化疗的卵巢癌、输卵管癌及原发腹膜腺癌患者中有一定的临床疗效,患者的总体耐受性较好,可作为该类患者的治疗选择。Objective：To investigate the efficacy and safety of nanoparticle albumin bound paclitaxel（NAB-P） based chemotherapy in recurrent ovarian cancer, fallopian tube cancer and primary peritoneal cancer. Methods： 21 Patients who treated with NAB-P based chemotherapy from March 2012 to December 2013 at Department of Gynecology,Peking University Cancer Hospital ＆ Institute were analyzed retrospectively. Response was evalua- ted. According to GCIG or RECIST criteria. Changes in the abundance of circulating CA125 ,adverse drug reactions occurred in patients and treatment delay and interruption during chemotherapy reflected the therapy response of these cancer patients. Results：33.3% （7/21） and 66.7% （ 14/21 ） of the patients were platinum-sensitive and primary/sencondary platinum resistant/refractory, respectively. At baseline, 18 （85. 7% ） had elevation of CA125. The overall response rate was 28.6% （6/21）, with CA12s complete responses in 6 patients. Response rate was 42.9% （3/7）in platinum-sensitive and 21.4% （3/14） in platinum resistant/refractory recurrences with no statisti- cal difference（ P 〉0.05）. 4 patients had treatment interruptions because of bone marrow suppression. Conclu- sions：Our data reveals that NAB-P based chemotherapy appears to be a promising approach in the therapy of platinum sensitive or platinum resistant patients and are generally well tolerated in heavily pretreated patients with epithelial ovarian cancer,fallopian tube cancer and primary peritoneal cancer.

关 键 词：白蛋白结合型紫杉醇 复发性卵巢癌 顺铂 

分 类 号：R737.3[医药卫生—肿瘤]